Roivant Sciences Ltd. $ROIV Stock: Oregon Public Employees Retirement Fund Grows Stake

Oregon Public Employees Retirement Fund raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 20.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 112,252 shares of the company’s stock after buying an additional 19,100 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Roivant Sciences were worth $4,105,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ROIV. Alpine Bank Wealth Management acquired a new position in shares of Roivant Sciences during the 3rd quarter worth about $25,000. Parallel Advisors LLC raised its position in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Bessemer Group Inc. raised its position in shares of Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares during the period. Root Financial Partners LLC bought a new position in Roivant Sciences during the 3rd quarter worth approximately $120,000. Finally, Acropolis Investment Management LLC bought a new position in Roivant Sciences during the 3rd quarter worth approximately $134,000. Institutional investors own 64.76% of the company’s stock.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total transaction of $7,022,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,399,154 shares in the company, valued at approximately $49,124,296.94. This trade represents a 12.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the transaction, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. The trade was a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,022,688 shares of company stock valued at $73,438,636 over the last ninety days. 8.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ROIV shares. Wolfe Research cut shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. UBS Group set a $55.00 target price on shares of Roivant Sciences in a report on Wednesday, September 9th. Citigroup lifted their price target on shares of Roivant Sciences from $46.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, HC Wainwright boosted their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.55.

Roivant Sciences Stock Down 4.2%

Shares of NASDAQ ROIV opened at $36.62 on Friday. Roivant Sciences Ltd. has a 1-year low of $19.79 and a 1-year high of $42.50. The company has a fifty day moving average price of $36.66 and a 200 day moving average price of $31.72.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.